Histological assessment of follicular delivery of flutamide by solid lipid nanoparticles: potential tool for the treatment of androgenic alopecia

Hamishehkar, Hamed; Ghanbarzadeh, Saeed; Sepehran, Sasan; Javadzadeh, Yousef; Adib, Zahra Mardhiah; Kouhsoltani, Maryam

doi:10.3109/03639045.2015.1062896

Cited by 51 publications

(33 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean particle size of lipid nanoparticles usually depends on several factors, such as type and concentration of lipid surfactants and the viscosity in lipid phases. 4 To avoid interfering with other effective parameters in skin penetration, the total amounts of lipid phase and surfactant were kept constant. The speed of homogenizer and the process time were changed to provide three SLN formulations with distinctly different submicron particle sizes.…”

Section: Resultsmentioning

confidence: 99%

“…The images were taken from normal light and fluorescence microscope of the same area and the dye distribution in the skin was evaluated qualitatively. 4 …”

Section: Characterization Of Rhodamine B-loaded Slnmentioning

confidence: 99%

“…Rhodamine B-loaded SLNs (0.004 %) were obtained by allowing the hot nanoemulsion to cool down at room temperature. 4 The Rhodamine B aqueous solution (Poloxamer 3% w/v) in the same concentration of SLNs formulation dispersion was used as control. Formulations was used for skin penetration experiments within one month after preparation since our experiments showed size stability of SLNs at least for one month.…”

Section: Preparations Of Rhodamine B-loaded Slnmentioning

confidence: 99%

“…Solid lipid nanoparticles (SLNs) are one of the main subclasses of lipid based nanocarriers which attracted major attention in dermal drug delivery. 4 SLNs are colloidal carriers developed in 1991 as an alternative to traditional colloidal carriers, such as emulsions, liposomes, and polymeric micro-and nanoparticles, to overcome their drawbacks by protecting the incorporated drug against degradation and providing size stability during storage time, biocompatibility and biodegradability, respectively. 5 Additionally, SLNs show many other advantages, such as control and target drug release, easy scale up, enhanced bioavailability of entrapped bioactive compounds, composition of physiological compounds or toxicologically-acceptable compounds, and avoidance of organic solvents.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The Effect of Particle Size on the Deposition of Solid Lipid Nanoparticles in Different Skin Layers: A Histological Study

Adib¹,

Ghanbarzadeh²,

Kouhsoltani³

et al. 2016

Adv Pharm Bull

Self Cite

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

“…The images were taken from normal light and fluorescence microscope of the same area and the dye distribution in the skin was evaluated qualitatively. 4 …”

Section: Characterization Of Rhodamine B-loaded Slnmentioning

confidence: 99%

Section: Preparations Of Rhodamine B-loaded Slnmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Effect of Particle Size on the Deposition of Solid Lipid Nanoparticles in Different Skin Layers: A Histological Study

Adib¹,

Ghanbarzadeh²,

Kouhsoltani³

et al. 2016

Adv Pharm Bull

Self Cite

View full text Add to dashboard Cite

“…This result contradicts the report by Patzelt et al, who showed that reductions in particle size (643 nm, 470 nm, 300 nm, and 122 nm) led to a significant reduction in particle penetration depth. 25,26 Transportation through the skin was limited to molecules with certain properties (molecular weight < 500 Dalton, moderate lipophilicity with octanolwater partition coefficient between 10 and 1000, and melting point < 200 °C). 4,27 However, additional means is usually required to increase transportation through the skin.…”

Section: Preparation Of Naga-loaded Nlcsmentioning

confidence: 99%

Nanostructured Lipid Carrier for Topical Application of N-Acetyl Glucosamine

et al. 2016

Self Cite

View full text Add to dashboard Cite

An appraisal of laboratory models of androgenetic alopecia: A systematic review

Ntshingila

Khumalo

Engel

et al. 2021

Skin Health and Disease

View full text Add to dashboard Cite

Background: Androgenetic alopecia (AGA) is the most common form of non-scarring alopecia in humans. Several studies have used different laboratory models to study the pathogenesis and interventions for AGA. These study models have proved beneficial and have led to the approval of two drugs. However, the need to build on existing knowledge remains by examining the relevance of study models to the disease. Objective: We sought to appraise laboratory or pre-clinical models of AGA. Method: We searched through databases (PubMed, ScienceDirect, Web of Science, World CAT, Scopus and Google Scholar) for articles on AGArelated studies from 1942 to March 2019 with a focus on study models. Results: The search rendered 101 studies after screening and deduplication. Several studies (70) used in vitro models, mostly consisting of twodimensional monolayer cells for experiments involving the characterization of androgen and 5-alpha reductase (5AR) and inhibition thereof, the effects of dihydrotestosterone (DHT) and biomarker(s) of AGA. Twenty-seven studies used in vivo models of mice and monkeys to investigate DHT synthesis, the expression and inhibition of 5AR and hair growth. Only four studies used AGA-related or healthy excisional/punch biopsy explants as ex vivo models to study the action of 5AR inhibitors and AGA-associated genes. No study used three-dimensional [3-D] organoids or organotypic human skin culture models. Conclusion:We recommend clinically relevant laboratory models like human or patient-derived 3-D organoids or organotypic skin in AGA-related studies. These models are closer to human scalp tissue and minimize the use of laboratory animals and could ultimately facilitate novel therapeutics. | BACKGROUNDAndrogenetic alopecia (AGA) is the most common form of non-scarring hair loss in humans. [1][2][3] The prevalence of AGA varies between races and ethnicities. 1 This disparity is attributed to the different methods of measuring prevalence, making it difficult to compare studies. 1,2 Nonetheless, about 50% of men of European descent are affected by the age of 50 years; this proportion increases to 90% with age. 1,4,5 Furthermore, AGA is estimated to affect about 19% of women of European ancestry, while the prevalence and severity of AGA are considered low in Asian and African men. 1,4,6 In the early 1940s, Hamilton proved that genetic predisposition and male hormone stimulation are prerequisites in AGA development. 7 After this discovery, several AGA models were created to delineate the pathophysiology and evaluate the effectiveness of novel therapeutics using both laboratory (in vitro, in vivo and ex vivo) and non-laboratory models. These models,This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

Histological assessment of follicular delivery of flutamide by solid lipid nanoparticles: potential tool for the treatment of androgenic alopecia

Abstract: It was concluded Flutamide-loaded SLN formulation can be used as a promising colloidal drug carriers for topical administration of Flutamide in the treatment of androgenic alopecia.

Cited by 51 publications

References 45 publications

The Effect of Particle Size on the Deposition of Solid Lipid Nanoparticles in Different Skin Layers: A Histological Study

The Effect of Particle Size on the Deposition of Solid Lipid Nanoparticles in Different Skin Layers: A Histological Study

Nanostructured Lipid Carrier for Topical Application of N-Acetyl Glucosamine

An appraisal of laboratory models of androgenetic alopecia: A systematic review

Contact Info

Product

Resources

About